Navigation Links
Research offers promising new approach to treatment of lung cancer
Date:5/22/2013

CORVALLIS, Ore. Researchers have developed a new drug delivery system that allows inhalation of chemotherapeutic drugs to help treat lung cancer, and in laboratory and animal tests it appears to reduce the systemic damage done to other organs while significantly improving the treatment of lung tumors.

This advance in nanomedicine combines the extraordinarily small size of nanoparticles, existing cancer drugs, and small interfering RNA (siRNA) that shut down the ability of cancer cells to resist attack.

The combination of these forces resulted in the virtual disappearance of lung tumors in experimental animals.

Lung cancer is the leading cancer killer in both men and women. Despite advances in surgery, chemotherapy still plays a major role in its treatment. However, that treatment is constrained by the toxic effects of some drugs needed to combat it and the difficulty of actually getting those drugs into the lungs.

The findings were made by Oleh Taratula at Oregon State University and Tamara Minko and O. Garbuzenko at Rutgers University and the Cancer Institute of New Jersey. They were just published in the Journal of Controlled Release.

"Lung cancer damage is usually not localized, which makes chemotherapy an important part of treatment," said Taratula, an assistant professor in the OSU College of Pharmacy and co-author on this study. "However, the drugs used are toxic and can cause organ damage and severe side effects if given conventionally through intravenous administration.

"A drug delivery system that can be inhaled is a much more efficient approach, targeting just the cancer cells as much as possible," he said. "Other chemotherapeutic approaches only tend to suppress tumors, but this system appears to eliminate it."

A patent is being applied for on the technology, and more testing will be necessary before it is ready for human clinical trials, the researchers said.

The foundation of the new system is a "nanostructured lipid nanocarrier," tiny particles much smaller than a speck of dust that are easily inhaled and also readily attach to cancer cells. This carrier system delivers the anticancer drug. However, it also brings siRNA that makes the cancer cell more vulnerable.

Cancer cells often have two forms of resistance to drugs "pump" resistance that tends to pump the drug out of cells, and "nonpump" resistance that helps keep the cell from dying. The siRNA used in this system helps to eliminate both those forms of resistance, and leaves the cancer cell vulnerable to the drug being used to kill it.

By being inhaled, this system also avoids degradation of the chemotherapeutic agents that occurs when they are injected, researchers said. They arrive in more intact form, ready to do their job on lung cancer cells, while minimizing any side effects.

In more conventional chemotherapy for lung cancer, the drugs tend to accumulate in the liver, kidney and spleen, with much less of the drugs ever making it to the lungs. In this study, the amount of the drug delivered to the lungs rose to 83 percent with the inhalation approach, versus 23 percent with injection.


'/>"/>

Contact: Oleh Taratula
oleh.taratula@oregonstate.edu
541-737-3424
Oregon State University
Source:Eurekalert

Related medicine news :

1. Insulin Pump Therapy Provides Better Glycemic Control Among Type 1 Diabetics, According to Kantar Health Research
2. Protease Leads Feed Enzyme Market as Compared to Phytase & NSP Says New Research Report at ReportsnReports.com
3. Researchers find genetic risk factor for pulmonary fibrosis
4. Researchers find genetic tie to improved survival time for pulmonary fibrosis
5. Research at the cutting edge of knowledge
6. Fertility Clinics in Australia Industry Market Research Report Now Available from IBISWorld
7. Iowa VP for Research addresses next-generation supercomputers at congressional hearing
8. JPIDS: Releases consensus statement on research definitions for drug-resistant TB in children
9. Adeptia Featured in Recent 451 Research Impact Report
10. NYUs Movshon receives Lashley Award for his research on the neuroscience of vision
11. New multi-million dollar research center aims to solve the mystery of premature birth
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/3/2016)... ... , ... Boston Children’s Hospital today announced its new pediatric Simulation (SIM) Center ... rare procedures in an environment that looks and feels real. , Located in the ... and “hackers” to develop and test new devices or software platforms and see how ...
(Date:5/3/2016)... , ... May 03, 2016 , ... Each year, about ... cause of death across the United States and account for one death every four ... impairments or are permanently disabled. HCR ManorCare is launching a video series called “Your ...
(Date:5/3/2016)... (PRWEB) , ... May 03, 2016 , ... Ogawa World ... with its user friendly Samsung tablet and exclusive Smart Application. The Smart 3D combines ... Starting each massage with a customized user profile and specialized massage program, each user ...
(Date:5/3/2016)... (PRWEB) , ... May 03, 2016 , ... ... the healthcare industry, announced today that Legacy Health is expanding its use of ... platform), after a highly successful initial proof of concept. The Portland, Oregon based ...
(Date:5/3/2016)... VA (PRWEB) , ... May 03, 2016 , ... ... provider of innovative information technology (IT) solutions and digital consulting services to the ... Information Technology Services (EITS) Indefinite Delivery / Indefinite Quantity (ID/IQ) contract in support ...
Breaking Medicine News(10 mins):
(Date:4/29/2016)... April 29, 2016 ... Financier Sanofi, leader mondial ... ses résultats pour le premier trimestre ... Jérôme Contamine, commente les résultats du ... perspectives pour le reste de l,année. ...
(Date:4/28/2016)... Research and Markets has announced ... Market 2016-2020" report to their offering. ... The global plastic surgery products market is expected to ... 2016-2020. , ,The growing adoption of laser in aesthetics ... the market. Lasers are used to treat a broad ...
(Date:4/28/2016)... 28, 2016 , Net Sales of $1.90 ... over the prior year period, and an increase of 1.2% ... Diluted EPS for the first quarter were $0.52 reported, a ... adjusted, an increase of 29.9% over the prior year period ... earnings guidance for 2016 Zimmer Biomet Holdings, Inc. ...
Breaking Medicine Technology: